<h1>100% tariff on branded pharma imports and steep H-1B fee hike spark investor selloff, weighing on pharma, IT stocks</h1> US administration announced a 100% tariff on imports of branded or patented pharmaceutical products effective October 1, and a concurrent steep H-1B visa fee increase has prompted sectoral and cross-border investor reactions. Indian equity benchmarks fell in early trade, with pharma and IT stocks among laggards, while select heavyweights gained. Foreign institutional investors registered significant net equity sales, exacerbating downward pressure. Market commentary ties the declines to the tariff and visa fee measures, weaker global cues and rising oil prices, noting substantial FIIs offloading that may sustain market weakness.